Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

86 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prospective analysis of factors precluding the initiation of durvalumab from an interim analysis of a phase II trial of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small cell lung cancer in Japan (SAMURAI study).
Tanzawa S, Makiguchi T, Tasaka S, Inaba M, Ochiai R, Nakamura J, Inoue K, Kishikawa T, Nakashima M, Fujiwara K, Kohyama T, Ishida H, Kuyama S, Miyazawa N, Nakamura T, Miyawaki H, Oda N, Ishikawa N, Morinaga R, Kusaka K, Miyamoto Y, Yokoyama T, Matsumoto C, Tsuda T, Ushijima S, Shibata K, Shibayama T, Bessho A, Kaira K, Misumi T, Shiraishi K, Matsutani N, Seki N. Tanzawa S, et al. Among authors: bessho a. Ther Adv Med Oncol. 2022 Jul 29;14:17588359221116603. doi: 10.1177/17588359221116603. eCollection 2022. Ther Adv Med Oncol. 2022. PMID: 35923924 Free PMC article.
Triple combination chemotherapy with cisplatin, docetaxel, and irinotecan for advanced non-small cell lung cancer: a phase I/II trial.
Kiura K, Takigawa N, Segawa Y, Tabata M, Shibayama T, Gemba K, Bessho A, Fujimoto N, Takata I, Hotta K, Fujiwara K, Tokuda Y, Kuyama S, Shinkai T, Ueoka H, Tanimoto M; Okayama Lung Cancer Study Group. Kiura K, et al. Among authors: bessho a. J Thorac Oncol. 2007 Jan;2(1):44-50. doi: 10.1097/JTO.0b013e31802bafe2. J Thorac Oncol. 2007. PMID: 17410009 Free article. Clinical Trial.
A phase II trial of erlotinib monotherapy in pretreated patients with advanced non-small cell lung cancer who do not possess active EGFR mutations: Okayama Lung Cancer Study Group trial 0705.
Yoshioka H, Hotta K, Kiura K, Takigawa N, Hayashi H, Harita S, Kuyama S, Segawa Y, Kamei H, Umemura S, Bessho A, Tabata M, Tanimoto M; Okayama Lung Cancer Study Group. Yoshioka H, et al. Among authors: bessho a. J Thorac Oncol. 2010 Jan;5(1):99-104. doi: 10.1097/JTO.0b013e3181c20063. J Thorac Oncol. 2010. PMID: 19898258 Free article. Clinical Trial.
Comparison of the incidence and pattern of interstitial lung disease during erlotinib and gefitinib treatment in Japanese Patients with non-small cell lung cancer: the Okayama Lung Cancer Study Group experience.
Hotta K, Kiura K, Takigawa N, Yoshioka H, Harita S, Kuyama S, Yonei T, Fujiwara K, Maeda T, Aoe K, Ueoka H, Kamei H, Umemura S, Moritaka T, Segawa Y, Kawai H, Bessho A, Kato K, Tabata M, Tanimoto M. Hotta K, et al. Among authors: bessho a. J Thorac Oncol. 2010 Feb;5(2):179-84. doi: 10.1097/JTO.0b013e3181ca12e0. J Thorac Oncol. 2010. PMID: 20101144 Free article.
Phase II trial of gefitinib in combination with bevacizumab as first-line therapy for advanced non-small cell lung cancer with activating EGFR gene mutations: the Okayama Lung Cancer Study Group Trial 1001.
Ichihara E, Hotta K, Nogami N, Kuyama S, Kishino D, Fujii M, Kozuki T, Tabata M, Harada D, Chikamori K, Aoe K, Ueoka H, Hosokawa S, Bessho A, Hisamoto-Sato A, Kubo T, Oze I, Takigawa N, Tanimoto M, Kiura K. Ichihara E, et al. Among authors: bessho a. J Thorac Oncol. 2015 Mar;10(3):486-91. doi: 10.1097/JTO.0000000000000434. J Thorac Oncol. 2015. PMID: 25695221 Free article. Clinical Trial.
Development of a skin rash within the first week and the therapeutic effect in afatinib monotherapy for EGFR-mutant non-small cell lung cancer (NSCLC): Okayama Lung Cancer Study Group experience.
Kudo K, Hotta K, Bessho A, Nogami N, Kozuki T, Kuyama S, Inoue K, Harita S, Okada T, Gemba K, Fujii M, Takigawa N, Oda N, Tanimoto M, Kiura K. Kudo K, et al. Among authors: bessho a. Cancer Chemother Pharmacol. 2016 May;77(5):1005-9. doi: 10.1007/s00280-015-2910-9. Epub 2016 Mar 31. Cancer Chemother Pharmacol. 2016. PMID: 27029623
A phase II study of topotecan and cisplatin with sequential thoracic radiotherapy in elderly patients with small-cell lung cancer: Okayama Lung Cancer Study Group 0102.
Kubo T, Fujiwara K, Hotta K, Okada T, Kuyama S, Harita S, Ninomiya T, Kamei H, Hosokawa S, Bessho A, Maeda T, Kozuki T, Fujimoto N, Ninomiya K, Takemoto M, Kanazawa S, Takigawa N, Tabata M, Tanimoto M, Ueoka H, Kiura K. Kubo T, et al. Among authors: bessho a. Cancer Chemother Pharmacol. 2016 Oct;78(4):769-74. doi: 10.1007/s00280-016-3135-2. Epub 2016 Aug 20. Cancer Chemother Pharmacol. 2016. PMID: 27544764 Clinical Trial.
Three-Arm Randomized Trial of Sodium Alginate for Preventing Radiation-Induced Esophagitis in Locally Advanced Non-Small Cell Lung Cancer Receiving Concurrent Chemoradiotherapy: The OLCSG1401 Study Protocol.
Ninomiya K, Ichihara E, Hotta K, Sone N, Murakami T, Harada D, Oze I, Kubo T, Tanaka H, Kuyama S, Kishino D, Bessho A, Harita S, Katsui K, Tanimoto M, Kiura K. Ninomiya K, et al. Among authors: bessho a. Clin Lung Cancer. 2017 Mar;18(2):245-249. doi: 10.1016/j.cllc.2016.08.001. Epub 2016 Oct 19. Clin Lung Cancer. 2017. PMID: 27847247 Clinical Trial.
86 results